AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14620385
Drug: Wood creosote
RxNorm normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wood creosote (up to 225 mg)
Trial: 8890679
Drug: Fluoxetine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (all doses combined)
Trial: 6367325
Drug: Subcutaneous dihydroergotamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous dihydroergotamine
Trial: 30201053
Drug: Improved treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved treatment as usual (iTAU)
Trial: 23212185
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl patches (TFPs) 25 μg, two patches placed 12 h before surgery
Trial: 23212185
Drug: Placebo patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patches of identical size
Trial: 22851577
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion after exercise
Trial: 22851577
Drug: Intralipid infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid infusion after exercise
Trial: 11879715
Drug: Simvastatin 20-mg
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20-mg per day
Trial: 7575120
Drug: Isolated limb
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated limb perfusion with high flow rate (869 +/- 122 mL/min)
Trial: 7575120
Drug: Isolated limb
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated limb perfusion with low flow rate (286 +/- 62 mL/min)
Trial: 26575524
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MFNS) 200 μg twice per day (BID)
Trial: 22487032
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of two delta rule learning processes
Trial: 19279300
Drug: High-fiber diet
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fiber diet (50 g total and 25 g soluble fiber)
Trial: 19279300
Drug: Moderate-fiber diet
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-fiber diet (24 g total and 8 g soluble fiber)
Trial: 17250692
Drug: Omalizumab (anti-IgE)
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab (anti-IgE) therapy
Trial: 7521090
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg DOX once in the AM
Trial: 7521090
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg DOX once in the PM
Trial: 7521090
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg DOX once in the AM
Trial: 7521090
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg DOX once in the PM
Trial: 2683019
Drug: Sucralfate (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (2 g taken 1/2 h before breakfast and at bedtime)
Trial: 29664896
Drug: Prazosin (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (16 mg daily for 6 weeks)
Trial: 29664896
Drug: Prazosin (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (in optimal treatment exposure subgroup)
Trial: 21051493
Drug: Remifentanil concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil concentrations (CeREMI) at 2, 4, or 6 ng m⁻¹ with propofol fixed at 3 µg ml⁻¹
Trial: 9627304
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone agonist (GnRH-a) therapy
Trial: 8157550
Drug: Ciprofloxacin 750
RxNorm normalized name: ciprofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 750 mg po
Trial: 31051498
Drug: AA-60 (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA-60 (8 AAs, 60 mmol/L Na+)
Trial: 31051498
Drug: AA-30 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA-30 (5 AAs, 30 mmol/L Na+)
Trial: 26148930
Drug: MPC injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPC injections (150 million cells)
Trial: 26148930
Drug: MPC injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPC injections (25 million cells)
Trial: 26148930
Drug: MPC injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPC injections (75 million cells)
Trial: 10664917
Drug: Naproxen (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (500 mg bid)
Trial: 27430621
Drug: Coaching plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coaching plus light therapy and pulsed electromagnetic field therapy for 12 weeks, twice a week for 40 min, and coaching once a fortnight for 50 min
Trial: 27430621
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with light and pulsed electromagnetic field switched to placebo settings for 12 weeks, twice a week for 40 min, and coaching once a fortnight for 50 min
Trial: 21755540
Drug: Asenapine 2
RxNorm normalized name: asenapine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine 2 mg BID for 2 days, then 5 mg BID for 2 days, then 10 mg BID thereafter (slow escalation)
Trial: 21755540
Drug: Asenapine 5
RxNorm normalized name: asenapine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine 5 mg BID for 4 days, then 10 mg BID thereafter (rapid escalation)
Trial: 19634922
Drug: Fibrin-specific lytic
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin-specific lytic (FSL) plus unfractionated heparin (UFH)
Trial: 14996675
Drug: Higher tidal
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher tidal volume ventilation (12 mL/kg of predicted weight)
Trial: 14996675
Drug: Lower tidal
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower tidal volume ventilation (6 mL/kg of predicted weight)
Trial: 11724641
Drug: Intravenous glutamate
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous glutamate infusion (125 mmol x l(‐1) at a rate of 1.5 ml x h(‐1) x kg(‐1) for 1 hour)
Trial: 11724641
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion (0.9% NaCl)
Trial: 3248354
Drug: Oxandrolone 2.5
RxNorm normalized name: oxandrolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone 2.5 mg/day for 3 months
Trial: 29695895
Drug: CBZ+BMT (Carbamazepine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBZ+BMT (Carbamazepine 200 mg, Betahistine Mesilate 12 mg or 18 mg, twice daily)
Trial: 29695895
Drug: OXC+BMT (Oxcarbazepine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXC+BMT (Oxcarbazepine 300 mg, Betahistine Mesilate 12 mg or 18 mg, twice daily)
Trial: 29695895
Drug: BMT 18
RxNorm normalized name: BMT IM
DrugBank: Biomodulin T (DB16529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMT 18 mg
Trial: 29695895
Drug: BMT 12
RxNorm normalized name: BMT IM
DrugBank: Biomodulin T (DB16529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMT 12 mg
Trial: 21710615
Drug: Antiresorptive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiresorptive treatment (alendronate, clodronate, denosumab, lasofoxifene, zoledronic acid)
Trial: 21710615
Drug: Antiresorptive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiresorptive treatment
Trial: 16915526
Drug: Isoproterenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol infusion (ISI)
Trial: 16915526
Drug: Sodium lactate
RxNorm normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium lactate infusion (SLI)
Trial: 3607806
Drug: Frusemide (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide (0.5 mg/kg intravenously)
Trial: 3607806
Drug: Isosorbide 5‐mononitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide 5‐mononitrate (15 mg intravenously)
Trial: 26260043
Drug: Dietitian referral
RxNorm normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietitian referral for medical nutrition therapy (RD)
Trial: 21467128
Drug: Aliskiren 300
RxNorm normalized name: aliskiren 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 300 mg/day
Trial: 21965488
Drug: Cyclobenzaprine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine (10 mg once per day before surgery, day of surgery, and first day after surgery)
Trial: 15225171
Drug: ibuprofen 800
RxNorm normalized name: ibuprofen 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen 800 mg three-times daily
Trial: 9198491
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml Gd-DTPA with three successive acquisitions at fixed intervals (25, 53 and 81 s)
Trial: 9198491
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml Gd-DTPA with individually determined MR acquisition start based on prior evaluation of contrast material transit times
Trial: 28939185
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (glue and antibiotic ointment)
Trial: 26438179
Drug: Propofol +
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol + remifentanil (5 ng.mL(‐1))
Trial: 19739696
Drug: Iloperidone (6-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloperidone (6-12 mg twice daily)
Trial: 12040346
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 or 60 mg given every 12 hours for 14 days)
Trial: 12040346
Drug: Ticlopidine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (250 mg twice daily for 14 days)
Trial: 9672165
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with alpha-interferon and lamivudine for 16 weeks
Trial: 7729237
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) 500 mg/day, administered seven to nine hours after awakening (R x 2)
Trial: 7729237
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) 500 mg/day, administered within two hours of awakening (R x 1)
Trial: 7729237
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) 500 mg/day, administered within two hours before bedtime (R x 3)
Trial: 2686410
Drug: Ciprofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (200 mg every 12 hours intravenously, then oral)
Trial: 2686410
Drug: Ceftazidime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (1 to 2 g intravenously every eight to 12 hours)
Trial: 31120118
Drug: Rivaroxaban (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (oral factor Xa inhibitor) given at the approved dose for PE for ≥3 months
Trial: 31120118
Drug: Rivaroxaban (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (oral factor Xa inhibitor)
Trial: 25688780
Drug: Varenicline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (1 mg twice daily for 24 weeks)
Trial: 16287132
Drug: BNS (nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNS (nutrition support delivered before treatment)
Trial: 16287132
Drug: TNS (nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNS (nutrition support delivered during treatment)
Trial: 11162750
Drug: adjunctive remacemide
RxNorm normalized name: Remacemide
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adjunctive remacemide hydrochloride 150 mg q.i.d. for 4 weeks
Trial: 11162750
Drug: adjunctive remacemide
RxNorm normalized name: Remacemide
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adjunctive remacemide hydrochloride
Trial: 9057729
Drug: IVIg (0.15-0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg (0.15-0.2 g/kg bodyweight, monthly for 2 years)
Trial: 8392903
Drug: Cisplatin 60
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 60 mg/m2, etoposide 120 mg/m2 x 3, and escalating epirubicin starting from 45 mg/m2 every 3 weeks for six courses (Group A)
Trial: 8392903
Drug: Cisplatin 60
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 60 mg/m2, etoposide 120 mg/m2 x 3, and escalating epirubicin with GM-CSF priming from day -17 to -7 (Group C)
Trial: 4004191
Drug: Amoxicillin-clavulanic acid
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanic acid (250 mg + 125 mg) three times daily for 7 days
Trial: 4004191
Drug: Cephalexin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin (250 mg) three times daily for 7 days
Trial: 4004191
Drug: Amoxicillin-clavulanic acid
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanic acid (for ampicillin-resistant strains)
Trial: 30807663
Drug: GSK561679 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK561679 350 mg/day for 6 weeks
Trial: 30029620
Drug: Dihydroartemisinin-piperaquine administered
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine administered in the community without an SMS reminder
Trial: 30029620
Drug: Dihydroartemisinin-piperaquine administered
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine administered in the community with an SMS reminder
Trial: 30029620
Drug: Dihydroartemisinin-piperaquine administered
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine administered in the community with a community health worker reminder
Trial: 30029620
Drug: Dihydroartemisinin-piperaquine administered
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine administered at the hospital with an SMS reminder
Trial: 30029620
Drug: Dihydroartemisinin-piperaquine administered
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine administered at the hospital without an SMS reminder
Trial: 16198885
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (LAVI > 34 mL/m2)
Trial: 11477904
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg of tetramethylpyrazine (TMP) dripped intravenously after anesthesia and 1 mg/kg of TMP infused into oxygenator after CPB
Trial: 12764908
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no TMP treatment)
Trial: 7657041
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg every other day
Trial: 7657041
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg on weekends
Trial: 2784977
Drug: Propofol continuous
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol continuous infusion for 3 days
Trial: 20121889
Drug: Fish-oil supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish-oil supplement (4 g/day, n = 49)
Trial: 17956874
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase (fibrinolysis)
Trial: 12804125
Drug: Methylphenidate (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (various doses)
Trial: 6333182
Drug: Epidermal growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidermal growth factor, applied topically four times a day on the day of surgery and twice a day for two days thereafter.
Trial: 22469850
Drug: Chondroitin sulfate
RxNorm normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroitin sulfate and glucosamine hydrochloride (combination therapy)
Trial: 18595980
Drug: Synbiotics (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotics (4 probiotic species: Lactobacillus rhamnosus GG and LC705, Bifidobacterium breve Bb99, and Propionibacterium freudenreichii ssp shermanii) with 0.8 g of galactooligosaccharides, daily for 6 months after birth.
Trial: 18595980
Drug: Placebo, daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, daily for 6 months after birth.
Trial: 16149682
Drug: Combined antibiotic
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined antibiotic ophthalmic solution (neomycin sulfate, polymyxin B sulfate and gramicidin)
Trial: 10396665
Drug: Albunex 0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albunex 0.10 ml/kg
Trial: 10396665
Drug: Albunex 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albunex 0.15 ml/kg
Trial: 10396665
Drug: Albunex 0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albunex 0.20 ml/kg
Trial: 10396665
Drug: Albunex (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albunex (all doses)
Trial: 2123909
Drug: Intravenous propafenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propafenone (2 mg/kg body weight per 10 min)
Trial: 2123909
Drug: Intravenous flecainide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous flecainide (2 mg/kg per 10 min)
Trial: 22841452
Drug: Xylazine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylazine (loading dose: 1mg/kg, CRI: 0.69mg/kg/h for 2h)
Trial: 22841452
Drug: Romifidine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romifidine (loading dose: 80μg/kg, CRI: 30μg/kg/h for 2h)
Trial: 21199965
Drug: Donepezil and
RxNorm normalized name: donepezil and memantine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil and antidepressant therapy
Trial: 19880458
Drug: Citalopram (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (initial treatment)
Trial: 19880458
Drug: Subsequent randomized
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent randomized trials (switching or augmenting treatments)
Trial: 19880458
Drug: Two vigorous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two vigorous medication trials
Trial: 19880458
Drug: Complicated medication
RxNorm normalized name: AVOBENZONE 3 g in 100 g / HOMOSALATE 10 g in 100 g / OCTISALATE 5 g in 100 g / OCTOCRYLENE 10 g in 100 g / OXYBENZONE 5 g in 100 g TOPICAL AEROSOL, SPRAY [UNCOMPLIKATED MAKEUP SETTING SPF 50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complicated medication regimens
Trial: 9516030
Drug: Acetaminophen 0.5
RxNorm normalized name: ACETAMINOPHEN 0.5 g in 1 g ORAL TABLET [Acetaminophen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 0.5 g
Trial: 2971603
Drug: Norfloxacin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (800 mg by mouth)
Trial: 2971603
Drug: Spectinomycin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spectinomycin (2 g intramuscularly)
Trial: 24384584
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide (ANP) infusion at 0.0125 μg(−1) kg(−1) min
Trial: 26277524
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no HBO therapy)
Trial: 20598107
Drug: IV iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV iron sucrose (Venofer(®), 200 mg)
Trial: 20598107
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron sulphate (Duroferon(®), 20×100 mg)
Trial: 16286670
Drug: Chronic L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic L-carnitine L-tartrate supplementation
Trial: 16286670
Drug: Acute L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute L-carnitine L-tartrate supplementation
Trial: 11203580
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of polylactide membrane plus polyglactin root‐lining mesh (Vicryl) and demineralized freeze‐dried bone allograft (DFDBA) (GVB sites)
Trial: 9302150
Drug: Fleroxacin 200
RxNorm normalized name: fleroxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 200 mg once daily
Trial: 8365829
Drug: Albuterol (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (360 micrograms total dose, 90 micrograms per dose, 4 doses)